Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ABOS

ABOS - Acumen Pharmaceuticals, Inc. Stock Price, Fair Value and News

2.93USD-0.14 (-4.56%)Market Closed

Market Summary

ABOS
USD2.93-0.14
Market Closed
-4.56%

ABOS Stock Price

View Fullscreen

ABOS RSI Chart

ABOS Valuation

Market Cap

176.0M

Price/Earnings (Trailing)

-3.15

Price/Sales (Trailing)

17.09

Price/Free Cashflow

-3.47

ABOS Price/Sales (Trailing)

ABOS Profitability

Return on Equity

-21.35%

Return on Assets

-18.59%

Free Cashflow Yield

-28.83%

ABOS Fundamentals

ABOS Revenue

Revenue (TTM)

10.8M

ABOS Earnings

Earnings (TTM)

-55.9M

Earnings Growth (Yr)

-31.54%

Earnings Growth (Qtr)

9.84%

Breaking Down ABOS Revenue

Last 7 days

11.8%

Last 30 days

25.8%

Last 90 days

-7.0%

Trailing 12 Months

-60.5%

How does ABOS drawdown profile look like?

ABOS Financial Health

Current Ratio

30.2

Debt/Equity

0.12

Debt/Cashflow

-1.68

ABOS Investor Care

Shares Dilution (1Y)

46.45%

Diluted EPS (TTM)

-1.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20236.6M0010.8M
20220002.4M
20200001.4M

Tracking the Latest Insider Buys and Sells of Acumen Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 19, 2024
oconnell daniel joseph
sold
-52,753
3.4706
-15,200
president and ceo
Jan 19, 2024
meisner derek m
sold
-31,048
3.4757
-8,933
chief legal officer & corp sec
Jan 18, 2024
barton russell
sold
-10,555
3.7258
-2,833
chief operating officer
Jan 18, 2024
siemers eric
sold
-11,603
3.7144
-3,124
chief medical officer
Jan 18, 2024
zuga matt
sold
-15,716
3.705
-4,242
cfo & chief business officer
Jan 02, 2024
meisner derek m
acquired
-
-
91,000
chief legal officer & corp sec
Jan 02, 2024
zuga matt
acquired
-
-
106,000
cfo & chief business officer
Jan 02, 2024
oconnell daniel joseph
acquired
-
-
401,000
president and ceo
Jan 02, 2024
siemers eric
acquired
-
-
94,000
chief medical officer
Jan 02, 2024
barton russell
acquired
-
-
73,000
chief operating officer

1–10 of 39

Which funds bought or sold ABOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Kelly Financial Services LLC
unchanged
-
198
3,824
-%
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-52,000
-
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-91,000
-
-%
May 17, 2024
Ikarian Capital, LLC
reduced
-15.49
-131,554
1,079,060
0.12%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-0.72
109,293
2,431,030
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
added
67.31
380,802
878,850
-%
May 15, 2024
CITADEL ADVISORS LLC
reduced
-82.19
-408,913
94,572
-%
May 15, 2024
Parkman Healthcare Partners LLC
reduced
-4.45
18,033
2,335,460
0.29%
May 15, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
sold off
-100
-65,007
-
-%
May 15, 2024
Integrated Wealth Concepts LLC
reduced
-30.82
-15,159
40,905
-%

1–10 of 46

Are Funds Buying or Selling ABOS?

Are funds buying ABOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABOS
No. of Funds

Unveiling Acumen Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 06, 2024
franklin resources inc
5.8%
3,358,809
SC 13G
Jan 24, 2024
murray james b jr
4.6%
2,681,057
SC 13G/A
Jul 25, 2023
ra capital management, l.p.
25.9%
14,981,618
SC 13D/A
Feb 14, 2023
manning paul b
7.8%
3,205,128
SC 13G/A
Feb 14, 2023
deep track capital, lp
9.66%
3,952,000
SC 13G/A
Feb 14, 2023
sands capital ventures, llc
2.7%
1,124,729
SC 13G/A
Oct 07, 2022
blackrock inc.
2.8%
1,115,027
SC 13G/A
Feb 16, 2022
hardie molly g.
8.5%
3,451,152
SC 13G
Feb 15, 2022
manning paul b
9.9%
4,010,678
SC 13G

Recent SEC filings of Acumen Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 05, 2024
8-K
Current Report
May 14, 2024
8-K
Current Report
May 14, 2024
10-Q
Quarterly Report

Peers (Alternatives to Acumen Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-8.98% -3.09%
-7.79
6.94
-64.45% -224.75%
29.9B
2.0B
53.85% 15.29%
-90.16
14.95
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.8B
2.5B
-0.97% -4.31%
77.02
6.4
13.74% 186.89%
14.7B
3.8B
6.43% 3.96%
19.69
3.9
8.58% 129.81%
MID-CAP
4.9B
107.9M
-6.08% -24.75%
-8.88
48.09
54.84% -28.31%
4.6B
524.1M
-5.24% -6.22%
-11.04
8.79
394.93% 39.61%
3.9B
251.0M
7.93% 10.52%
-13.16
15.54
73.58% -86.73%
3.4B
240.7M
17.18% -20.08%
-7.26
12.77
-1.03% -213.92%
3.0B
813.8M
21.05% -43.59%
-1.7K
3.65
56.43% 98.83%
2.1B
996.6M
8.34% 84.22%
-5.26
2.1
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.69% 23.21%
30.33
4.8
60.38% -34.49%
565.8M
881.7K
20.84% 614.44%
-16.76
481.06
-77.61% 33.36%
269.0M
4.2M
21.26% 49.14%
-2.15
64.66
-66.30% 48.24%
18.2M
2.1M
-7.46% -80.82%
-0.79
7.61
-13.45% 69.54%

Acumen Pharmaceuticals, Inc. News

Latest updates
Defense World44 hours ago
American Banking and Market News14 Jul 202406:35 am

Acumen Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q12022Q42020Q42020Q32020Q2
Revenue37.2%4,0052,9191,8321,4651,097730151
Operating Expenses-3.9%17,77418,48613,13514,249-3,2202,186
  S&GA Expenses2.5%5,3255,1934,4223,503-226259
  R&D Expenses-6.3%12,44913,2938,71310,746-2,9941,927
Interest Expenses-1,000------
Income Taxes--------
Net Income9.8%-14,873-16,497-11,307-12,866--2,490-2,035
Net Income Margin-6.8%-5.18*-4.85*-6.83*-17.92*-5.10*--
Free Cashflow-114.8%-17,859-8,314-10,175-11,203---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-3.0%30131028617718819720321222023023573.0044.00
  Current Assets3.7%25624721915014418020319119219920571.0044.00
    Cash Equivalents-29.8%47.0067.0095.0077.0078.0013015811110912213669.0044.00
  Net PPE-4.1%0.000.000.000.000.000.000.000.000.000.000.000.00-
Liabilities-9.8%39.0043.006.009.009.008.007.005.004.005.001.005.006.00
  Current Liabilities-34.7%8.0013.006.009.009.008.007.005.004.005.00---
  Long Term Debt1.0%30.0030.00-----------
Shareholder's Equity-1.8%262267280169179189197207216225233--
  Retained Earnings-6.7%-237-222-206-193-181-170-157-146-136-127-119-115-27.00
  Additional Paid-In Capital2.1%5004894873633613603553543543533539.008.00
Shares Outstanding3.7%60.0058.0058.0041.0041.0041.0040.0040.0040.0040.0013.00-0.00
Float----134---135-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations-114.8%-17,859-8,314-12,905-11,670-10,175-11,203-9,183-6,468-8,299-3,639-7,688-4,264-2,370---
  Share Based Compensation52.0%2,4841,6341,6001,5211,390888840715618365304127126---
Cashflow From Investing81.1%-9,203-48,807-92,00111,064-41,927-20,42055,9198,785-5,099-------
Cashflow From Financing-75.6%7,10729,134122,764-145-4,184-263--10.00168,781-----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABOS Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 12,449$ 8,713
General and administrative5,3254,422
Total operating expenses17,77413,135
Loss from operations(17,774)(13,135)
Other income (expense)  
Interest income4,0051,832
Interest expense(1,000)0
Change in fair value of embedded derivatives(50)0
Other expense, net(54)(4)
Total other income2,9011,828
Net loss(14,873)(11,307)
Other comprehensive gain (loss)  
Unrealized loss on marketable securities(456)227
Comprehensive loss$ (15,329)$ (11,080)
Net loss per common share, basic (in dollars per share)$ (0.25)$ (0.28)
Net loss per common share, diluted (in dollars per share)$ (0.25)$ (0.28)
Weighted-average shares outstanding, basic (in shares)59,812,00041,025,062
Weighted-average shares outstanding diluted (in shares)59,812,00041,025,062

ABOS Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 46,930$ 66,886
Marketable securities, short-term205,582176,636
Prepaid expenses and other current assets3,3193,093
Total current assets255,831246,615
Marketable securities, long-term44,10862,553
Right-of-use asset353381
Restricted cash234233
Property and equipment, net117122
Other assets324221
Total assets300,967310,125
Current liabilities  
Accounts payable3,0791,379
Accrued clinical trial expenses2,3674,387
Accrued expenses and other current liabilities2,9056,339
Finance lease liability, short-term0756
Operating lease liability, short-term121110
Total current liabilities8,47212,971
Operating lease liability, long-term252284
Debt, long-term30,20929,897
Total liabilities38,93343,152
Commitments and contingencies (Note 10)
Stockholders’ equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively66
Additional paid-in capital499,843489,453
Accumulated deficit(237,671)(222,798)
Accumulated other comprehensive income (loss)(144)312
Total stockholders’ equity262,034266,973
Total liabilities and stockholders’ equity$ 300,967$ 310,125
ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
 CEO
 WEBSITEhttps://acumenpharm.com
 INDUSTRYBiotechnology
 EMPLOYEES39

Acumen Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Acumen Pharmaceuticals, Inc.? What does ABOS stand for in stocks?

ABOS is the stock ticker symbol of Acumen Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acumen Pharmaceuticals, Inc. (ABOS)?

As of Thu Jul 18 2024, market cap of Acumen Pharmaceuticals, Inc. is 176.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers.

What is the fair value of ABOS stock?

You can check ABOS's fair value in chart for subscribers. The fair value of Acumen Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acumen Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acumen Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ABOS is over valued or under valued. Whether Acumen Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Acumen Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABOS.

What is Acumen Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, ABOS's PE ratio (Price to Earnings) is -3.15 and Price to Sales (PS) ratio is 17.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABOS PE ratio will change depending on the future growth rate expectations of investors.